{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:22:19Z","timestamp":1792092139919,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.humpath.2023.08.001","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T23:10:44Z","timestamp":1691795444000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Eosinophils in metastatic melanoma"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-5418","authenticated-orcid":false,"given":"Sydney L.","family":"Proffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison M.","family":"Demer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.08.001_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.humpath.2023.08.001_bib2","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.08.001_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1158901","article-title":"Predictive immune markers in advanced melanoma patients treated with ipilimumab","volume":"5","author":"Umansky","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.humpath.2023.08.001_bib4","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.08.001_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.cji.0000211324.53396.f6","article-title":"Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors","volume":"30","author":"Lotfi","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.humpath.2023.08.001_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","article-title":"Eosinophils and cancer","volume":"2","author":"Davis","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.humpath.2023.08.001_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00262-012-1288-3","article-title":"Involvement of eosinophils in the anti-tumor response","volume":"61","author":"Gatault","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.humpath.2023.08.001_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2016.42","article-title":"Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study","volume":"29","author":"Prizment","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.08.001_bib9","unstructured":"Melanoma of the skin - cancer stat facts. SEER. Accessed August 13, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"10.1016\/j.humpath.2023.08.001_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1189\/jlb.0106027","article-title":"Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response","volume":"79","author":"Cormier","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.humpath.2023.08.001_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nri3861","article-title":"Granulocytes: eosinophils enable the antitumour T cell response","volume":"15","author":"Minton","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.humpath.2023.08.001_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.humpath.2023.08.001_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4067\/S0717-95022021000200512","article-title":"Inflammatory infiltrates in melanocytic lesions","volume":"39","author":"Relan","year":"2021","journal-title":"Int J Morphol"},{"key":"10.1016\/j.humpath.2023.08.001_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2015.04.029","article-title":"The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell","volume":"364","author":"Xie","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2023.08.001_bib15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","article-title":"Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors","volume":"95","author":"von Wasielewski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.001_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-015-0572-3","article-title":"Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting","volume":"13","author":"Lipson","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.humpath.2023.08.001_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41379-019-0402-x","article-title":"Melanoma pathology reporting and staging","volume":"33","author":"Scolyer","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.08.001_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies","volume":"53","author":"Ugurel","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2023.08.001_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1727116","article-title":"Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors","volume":"9","author":"Simon","year":"2020","journal-title":"Oncoimmun"},{"key":"10.1016\/j.humpath.2023.08.001_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/CJI.0b013e318174a512","article-title":"Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK\/LAK cells","volume":"31","author":"Capobianco","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.humpath.2023.08.001_bib21","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772300165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772300165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:41:58Z","timestamp":1758645718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681772300165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":21,"alternative-id":["S004681772300165X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.001","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophils in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}